GlassScriptPhysician profile
Monica Sam
NPI 1184115354
$7,467.76
in general payments reported to CMS, 2019-2025
21 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,894 · 2022: $120 · 2023: $1,113 · 2024: $838 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,758.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $695.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,350.50 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $485.79 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $302.12 | 2024-2025 | Rexulti, Abilify Mycite |
| Axsome Therapeutics, INC. | $286.66 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $255.21 | 2021-2025 | Mounjaro |
| Neurocrine Biosciences, INC. | $253.33 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $236.59 | 2025 | Fanapt |
| Gilead Sciences, INC. | $201.57 | 2023-2024 | |
| Abbvie INC. | $172.14 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $124.47 | 2025 | Invega Sustenna |
| Verona Pharma, INC. | $123.61 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $119.99 | 2025 | Tyvaso |
| Abbott Laboratories | $97.39 | 2025 | Freestyle Libre 3 |
| Braeburn INC. | $91.60 | 2025 | Brixadi |
| Glaxosmithkline, LLC. | $69.23 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $66.26 | 2025 | Cobenfy |
| Alkermes, INC. | $66.01 | 2024 | Lybalvi |
| Novo Nordisk INC | $58.97 | 2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $56.60 | 2021 | |
| Merck Sharp & Dohme LLC | $35.77 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.